---
title: "Insider Move at Biotech Firm Sparks Fresh Investor Interest"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298398581.md"
description: "Director Peter Marks purchased 47,620 shares of Alterity Therapeutics (ATHE) on Sept 8, 2026, signaling confidence. The stock is supported by bullish coverage of lead candidate ATH434 for multiple system atrophy, a new U.S. patent extending protection to 2045, and plans for securities quotation. Despite these catalysts, TipRanks' AI Analyst rates ATHE as Neutral due to weak financials, zero revenue, and negative earnings."
datetime: "2026-09-09T02:08:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298398581.md)
  - [en](https://longbridge.com/en/news/298398581.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298398581.md)
generator: "portal-rs"
---

# Insider Move at Biotech Firm Sparks Fresh Investor Interest

New insider activity at Alterity Therapeutics ( (ATHE) ) has taken place on September 8, 2026.

Director Peter Ashley Marks has strengthened his stake in Alterity Therapeutics by purchasing 47,620 shares of the company’s stock, in a transaction valued at $23,810. This insider buy may signal confidence in the company’s future prospects and could attract attention from investors watching management’s moves closely.

Alterity Therapeutics shares have been supported by bullish coverage focused on its lead candidate ATH434 in multiple system atrophy, where Phase 2 data and an FDA-aligned registrational path are seen as catalysts for long-term upside if Phase 3 confirms functional benefit. Additional optimism stems from a newly granted U.S. patent extending ATH434 protection to at least 2045 and the company’s move to seek quotation of ATH securities, which together enhance commercial visibility, potential partnering appeal, and flexibility for future capital raising despite current weak financials and challenging valuation metrics.

**Spark’s Take on ATHE Stock**

According to Spark, TipRanks’ AI Analyst, ATHE is a Neutral.

The score is held down primarily by weak financial performance (zero revenue in FY2026, large losses, and heavy cash burn), only partly offset by a low-debt balance sheet. Technicals are neutral-to-weak with the stock trading below key short- and mid-term moving averages, and valuation remains constrained due to negative earnings and no dividend.

To see Spark’s full report on ATHE stock,  
 click here. 

**More about Alterity Therapeutics**

**YTD Price Performance:** 47.40%

**Average Trading Volume:** 44,065

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $79.63M

### Related Stocks

- [ATHE.US](https://longbridge.com/en/quote/ATHE.US.md)
- [ATH.AU](https://longbridge.com/en/quote/ATH.AU.md)

## Related News & Research

- [Alterity Therapeutics Issues 8.4 Million Shares Under Underwriting Deal](https://longbridge.com/en/news/298249430.md)
- [Alterity Therapeutics Seeks Quotation for New ASX Shares](https://longbridge.com/en/news/299120002.md)
- [Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026 | ATHE Stock News](https://longbridge.com/en/news/293334270.md)
- [Alterity Therapeutics Files June 2026 Corporate Presentation With U.S. Regulator](https://longbridge.com/en/news/289902659.md)
- [Alterity Therapeutics issues 8,400,000 shares tied to exercised options at A$ 0.5 each](https://longbridge.com/en/news/298298137.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**